Coca-Cola cases recalled due to plastic contamination
Coca-Cola has issued a recall on select cases of its soda due to foreign object contamination.
Reyes Coca-Cola Bottling, LLC issued the voluntary recall earlier this month, according to a report shared by the Food and Drug Administration (FDA).
A total of 864 cases — each of which has 12 Coca-Cola cans — have been recalled because they were contaminated with plastic. This means that more than 10,000 cans of soda were affected by the recall.
According to the FDA, each of the affected cans has a UPC of 0 49000-00634 6. The targeted packs of 12 cans have a UPC of 0 49000-02890 4.
The recalled cases of Coca-Cola were distributed to retailers in Illinois and Wisconsin.
The action was classified as a 'Class II' recall on Monday, which is a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote,' according to the FDA.
The Independent has contacted Reyes Coca-Cola Bottling, LLC for comment.
The news comes as food and drink recalls continue to be on the rise.
Last week, Aldi issued a voluntary recall on 400 cases of Happy Farm's Colby Jack Deli Sliced Cheese, which included 12 plastic pouches of blended Colby and Monterey cheese slices each.
According to the FDA, the Aldi product may contain stainless steel fragments, and exposure to such contaminants could cause temporary health risks. It's unclear how the potential metal products got into the cheese.
Days earlier, Dessert Holdings, LLC announced that it was recalling a Target brand cheesecake. The product is Favorite Day's New York Style Cheesecake, sold in a six-ounce container with two slices of cake.
The cheesecake was recalled due to mislabeled packaging, resulting in undeclared pecans in the products. Customers who 'have an allergy or severe sensitivity to pecans run the risk of serious or life-threatening allergic reactions' if they consume this cheesecake, states a press release concerning the recall.
Recalled cheesecakes were sent to Target Distribution Centers in California, Florida, Iowa, Ohio, and Texas. The product was sold at Target stores in these states.
Also this month, Nestlé U.S. issued a voluntary recall on a limited supply of its Stouffer's and Lean Cuisine meals due to the potential presence of 'wood-like material.' The food conglomerate said the recalled products had been distributed 'at major retailers' between September 2024 and March 2025.
Nestlé said the company launched an investigation after consumers contacted them to report multiple issues — one involving a potential choking incident.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Chocolate company recalls product nationwide for undeclared allergen
NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CBS News
6 hours ago
- CBS News
Weaver Nut Company recalls chocolate nonpareils over undeclared milk allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. Recalled chocolate nonpareils. FDA Recalled chocolate nonpareils. FDA 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds) Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk.
Yahoo
10 hours ago
- Yahoo
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
Investing in biotech penny stocks is fraught with volatility, regulatory hurdles, and uncertain clinical results. Penny stocks are companies that trade for less than $5 per share. However, for those with a high risk tolerance, these small-cap stocks can provide outsized returns, particularly when scientific breakthroughs or U.S. Food and Drug Administration (FDA) approvals result in explosive gains. With Wall Street analysts issuing 'Strong Buy' ratings on these two high-potential plays, let's dig in to see whether these growth stocks could deliver on their promises. With a market capitalization of $21 million, Ovid Therapeutics is a small clinical-stage biopharmaceutical company focused on developing treatments for rare neurological disorders. Ovid's business model is centered on central nervous system (CNS) disorders, which are a challenging therapeutic area. Its pipeline includes novel compounds in early- to mid-stage development that target epilepsy and other genetically based neurological disorders. OVID stock has fallen 67.6% year-to-date (YTD), compared to the S&P 500 Index's ($SPX) gain of 1.6%. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Ovid currently has no FDA-approved products on the market. However, Wall Street analysts have called OVID a "Strong Buy," with all six analysts covering the stock rating it as such. Still, the company has also received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share. Ovid has until Aug. 11, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days. Ovid's pipeline is small in size but very targeted. The most closely watched candidate is OV329, a highly selective small-molecule inhibitor of GABA aminotransferase (GABA-AT). OV329 is intended to treat epilepsy that has not responded to previous treatments. In preclinical models, the candidate has shown promise in controlling seizures while causing fewer side effects than existing treatments such as vigabatrin. Ovid Therapeutics anticipates Phase 1 trial results in the third quarter of 2025. The company has a good chance of its stock ticking upwards if the Phase 1 topline results for OV329 turn out positive. Ovid's other candidate is OV350, a next-generation KCC2 modulator that is also being tested in a Phase 1 trial. The company generated $130,000 in revenue from royalty agreements during Q1. At the end of the quarter, its cash, equivalents, and marketable securities totaled $43 million. This gives the company an estimated runway through the second half of 2026. Ovid has received a 'Strong Buy' rating on Wall Street because of its rich pipeline of rare disease treatments. The stock may appeal to long-term aggressive investors who are comfortable with volatility and have a strong interest in innovative science. However, I believe investors should wait until Ovid either clears the $1 delisting threshold or proves its clinical strategy with positive results. Analysts have an average target price of $2.88 for the stock, which implies upside potential of 860% from current levels. The Street-high price estimate stands at $4 for OVID stock. With a market cap of $609 million, Nuvation Bio is a clinical-stage biotech company that develops targeted oncology treatments for challenging cancers with limited treatment options. However, it may soon release a revenue-generating product to the market this year. NUVB stock is down 27.7% YTD, compared to the overall market gain. Nuvation Bio's pipeline includes programs addressing a variety of oncology targets, including breast, ovarian, and lung cancer. Its pipeline currently consists of four core programs: taletrectinib (ROS1 inhibitor), NUV-1511 (drug-drug conjugate), safusidenib (brain-penetrant IDH1 inhibitor), and NUV-868 (BET inhibitor). Taletrectinib, Nuvation's lead candidate for the treatment of ROS1+ and advanced non-small cell lung cancer, has already been approved in China and the United States. The company hopes to begin commercializing taletrectinib in mid-2025. In March, the firm secured $250 million in non-dilutive financing from Sagard Healthcare Partners, as well as $150 million in royalty financing and $50 million in debt, subject to approval. Nuvation also has the option to secure an additional $50 million in debt until June 30, 2026 if it completes its first commercial sale in the United States. Safusidenib is currently in Phase 2 trials, and NUV-1511 is in Phase ½ trials. The company intends to provide updates for both during the second half of 2025. Nuvation ended Q1 with $461.7 million in cash, cash equivalents, and marketable securities. A favorable FDA decision could open up significant market opportunities for the company. Nuvation Bio's late-stage pipeline, strong cash position, and clear commercialization path make it an appealing biotech growth stock to buy right now. However, the company's ability to generate profits after commercialization may take years, making it an appropriate choice for those with a high risk tolerance and a longer investment horizon. Overall, Wall Street rates NUVB stock a 'Strong Buy.' Of the seven analysts covering the stock, six rate Nuvation as a 'Strong Buy' while one recommends a 'Moderate Buy" rating. The average price target of $7.17 suggests that NUVB stock could rally around 258% over the next 12 months. The high price estimate of $10 suggests a gain of 400% over current levels. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
